Hinge Health - HNGE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $49.36
  • Forecasted Upside: 5.87%
  • Number of Analysts: 16
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 15 Buy Ratings
  • 1 Strong Buy Ratings
$46.62
▼ -0.33 (-0.70%)

This chart shows the closing price for HNGE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Hinge Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HNGE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HNGE

Analyst Price Target is $49.36
▲ +5.87% Upside Potential
This price target is based on 16 analysts offering 12 month price targets for Hinge Health in the last 3 months. The average price target is $49.36, with a high forecast of $60.00 and a low forecast of $41.00. The average price target represents a 5.87% upside from the last price of $46.62.

This chart shows the closing price for HNGE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 16 investment analysts is to buy stock in Hinge Health.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/18/2025
  • 0 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/17/2025
  • 1 strong buy ratings
  • 15 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/17/2025

Latest Recommendations

  • 1 strong buy ratings
  • 15 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/14/2025CitigroupInitiated CoverageOutperform
7/14/2025JMP SecuritiesInitiated CoverageMarket Outperform$58.00
7/14/2025Citizens JmpInitiated CoverageStrong-Buy$58.00
7/14/2025KeyCorpBoost TargetOverweight ➝ Overweight$45.00 ➝ $60.00
7/14/2025BarclaysReiterated RatingOverweight ➝ Overweight$43.00 ➝ $51.00
6/16/2025William BlairInitiated CoverageOutperform
6/16/2025Truist FinancialInitiated CoverageBuy$48.00
6/16/2025Stifel NicolausInitiated CoverageBuy$48.00
6/16/2025Royal Bank Of CanadaInitiated CoverageOutperform$45.00
6/16/2025Raymond James FinancialInitiated CoverageOutperform$45.00
6/16/2025Piper SandlerInitiated CoverageOverweight$41.00
6/16/2025Morgan StanleyInitiated CoverageOverweight$46.00
6/16/2025Evercore ISIInitiated CoverageOutperform$50.00
6/16/2025Bank of AmericaInitiated CoverageBuy$42.00
6/16/2025Needham & Company LLCInitiated CoverageBuy$47.00
6/16/2025KeyCorpInitiated CoverageOverweight$45.00
6/16/2025Canaccord Genuity GroupInitiated CoverageBuy$52.00
6/16/2025BarclaysInitiated CoverageOverweight$43.00
(Data available from 7/18/2020 forward)

News Sentiment Rating

0.53 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/18/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/17/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/19/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/18/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/18/2025
  • 4 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/17/2025
  • 10 very positive mentions
  • 23 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/17/2025

Current Sentiment

  • 10 very positive mentions
  • 23 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Hinge Health logo
Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients. We have designed our platform to address a broad spectrum of MSK care—from acute injury, to chronic pain, to post-surgical rehabilitation. Members receive personalized and largely automated MSK care through our AI-powered motion tracking technology and a proprietary electrical nerve stimulation wearable device, all designed and monitored by our AI-supported care team of licensed physical therapists, physicians, and board-certified health coaches. Our platform can improve pain and function and reduce the need for surgeries, all while driving health equity by allowing members to engage in their exercise therapy sessions from anywhere and embrace movement as a way of life. There is no shortage of new technologies in the healthcare industry, yet the cost of care continues to rise. In other industries, the launch of new technologies has generally improved end-user experiences and lowered costs. In healthcare, however, new technologies have not always been successful in lowering the cost of care or improving clinical outcomes. We believe there are two key reasons for healthcare’s idiosyncratic response to technology: • Automating most aspects of care is difficult because so many healthcare interventions involve unstructured physical tasks. • The current framework for healthcare reimbursement has specific pathways to pay for care, which means new technologies are constrained to deliver within this framework. At Hinge Health, we have taken these challenges head-on. To address the automation of care, we have weaved together AI-enabled capabilities - such as our AI-powered motion tracking technology, TrueMotion, our proprietary FDA-cleared wearable device, Enso, and our AI-supported care team - to deliver scalable and personalized MSK care. According to our estimates based on data from 2024, our platform reduced the number of human care team hours associated with traditional physical therapy by approximately 95%. We have done this while improving our high member satisfaction over time. To address healthcare reimbursement constraints, we developed novel billing methods for our innovative technology by both directly selling to employers while also partnering with health plans, pharmacy benefit managers (“PBMs”), third-party administrators (“TPAs”), and other ecosystem entities to efficiently provide our platform to clients and members. While the MSK market is massive, existing solutions have fallen short as they are often expensive, ineffective, inconvenient to access, and delivered in a one-to-one or few-to-one care setting. Effective MSK care should be engaging, easy to use, and accessible anytime, anywhere. We developed Hinge Health to be simple and accessible, complete, personalized, and scalable. • Simple and accessible: We provide members access to our platform at no direct cost to them and without a copay or deductible. Members can access our broad spectrum of MSK care through a single on-demand app, designed to provide an engaging, seamless, and convenient digital experience whenever and wherever the member chooses. Potential members can complete a simple intake form, download the app, and start exercises soon thereafter. During the year ended December 31, 2024, approximately 64% of members were onboarded on the same day they completed their intake form, and approximately 75% of members were onboarded within the first week. • Complete: Our platform offers a wide range of support with multiple programs across many affected areas to provide a continuum of care from prevention to treatment of acute injury and chronic pain, as well as surgery decision support and post-surgical recovery. We also offer non-addictive and non-invasive pain relief via electrostimulation through our proprietary FDA-cleared wearable device, Enso, that is seamlessly integrated into our platform. • Personalized: Our platform delivers smarter care through AI and machine learning. Our AI model is trained on a large, proprietary MSK data set, and our technology is continuously learning and improving as each new member enrolls and engages with our programs, which creates a positive feedback loop. As of March 31, 2025, we had treated over one million members and our programs had tracked over 74 million activity sessions and 32 million member-reported outcome logs. We focus on personalization to keep members moving: from customized care plans to real-time in-app exercise feedback based on the member’s input and our proprietary motion tracking technology. • Scalable: Our AI-powered motion tracking technology, TrueMotion, allows us to deliver scalable and largely automated care. According to our estimates based on data from 2024, our platform reduced the number of human care team hours associated with traditional physical therapy by approximately 95%. While most of our programs provide members with access to a dedicated care team, our technology automates most aspects of care delivery while allowing our members to progress through their exercise therapy sessions on their own time. We have developed an efficient go-to-market model by working directly with our partners and clients. We seek to be the best solution on the market, the most validated solution on the market, and the easiest to buy. Our clients are primarily self-insured employers and include many of the nation’s leading enterprises across a broad range of industries and sizes. Within this segment, we also serve many public sector self-insured employers, such as state and local city governments and labor unions. In most instances, we partner with clients’ health plans, TPAs, PBMs, or other ecosystem entities to reduce the friction of contracting, procurement, security and IT reviews, onboarding, and billing. We are also in the early stages of expanding to serve health plans’ fully-insured and Medicare Advantage populations and federal insurance plans. As of December 31, 2024, we had approximately 20 million contracted lives across more than 2,250 clients. We had active client agreements with 49% of the Fortune 100 companies and 42% of the Fortune 500 companies, as of December 31, 2024. Despite this progress, our current contracted lives only represent 5% of our total addressable market. We believe that we grow efficiently because of our scalable, repeatable go-to-market model. We sell through our direct sales force and our partners. Once we contract with a client, we are most often the sole digital MSK care provider offered to their contracted lives. Our average contract term is three years. For the term of each contract, we are able to enroll, engage, and re-engage the client’s eligible lives, driving a recurring, repeatable revenue model, which is demonstrated in our net dollar retention of 117% as of December 31, 2024. Our 12-month client retention rate was 98% as of December 31, 2024. Additionally, we have a high level of client satisfaction, as shown by our client net promoter score (“NPS”) of 87 as of October 31, 2024. We also invested early in building our partner network. As of March 31, 2025, we had over 50 partners. Our partners include the five largest national health plans by self-insured lives, and the top three PBMs by market share. As of that date, we had retained 100% of our partners that we chose to work with since inception, excluding partners who were acquired. We have experienced significant growth since our inception, with a recurring revenue business model. As of December 31, 2024, we had over 532,000 members and more than 2,250 clients, compared to approximately 371,000 members and approximately 1,650 clients as of December 31, 2023. Our principal executive offices are located in San Francisco, California.
Read More

Today's Range

Now: $46.62
Low: $45.80
High: $47.71

50 Day Range

MA: N/A

52 Week Range

Now: $46.62
Low: $33.42
High: $52.16

Volume

506,789 shs

Average Volume

1,103,514 shs

Market Capitalization

$3.64 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Hinge Health?

The following Wall Street analysts have issued research reports on Hinge Health in the last year: Bank of America Corporation, Barclays PLC, Canaccord Genuity Group Inc., Citigroup Inc., Citizens Jmp, Evercore ISI, JMP Securities, KeyCorp, Morgan Stanley, Needham & Company LLC, Piper Sandler, Raymond James Financial, Inc., Royal Bank Of Canada, Stifel Nicolaus, Truist Financial Corporation, Wall Street Zen, and William Blair.
View the latest analyst ratings for HNGE.

What is the current price target for Hinge Health?

0 Wall Street analysts have set twelve-month price targets for Hinge Health in the last year. Their average twelve-month price target is $49.36, suggesting a possible upside of 5.9%. KeyCorp has the highest price target set, predicting HNGE will reach $60.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $41.00 for Hinge Health in the next year.
View the latest price targets for HNGE.

What is the current consensus analyst rating for Hinge Health?

Hinge Health currently has 15 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HNGE will outperform the market and that investors should add to their positions of Hinge Health.
View the latest ratings for HNGE.

What other companies compete with Hinge Health?

Other companies that are similar to Hinge Health include UL Solutions, Allegion, Stantec, Maplebear and QXO. Learn More about companies similar to Hinge Health.

How do I contact Hinge Health's investor relations team?

Hinge Health's physical mailing address is 455 MARKET STREET, 7TH FLOOR, SAN FRANCISCO, CA, 94105. The company's listed phone number is (415) 689-8429. The official website for Hinge Health is www.hingehealth.com. Learn More about contacing Hinge Health investor relations.